MX2023004147A - Proceso mejorado de preparación de nanopartículas lipídicas cargadas de arnm. - Google Patents
Proceso mejorado de preparación de nanopartículas lipídicas cargadas de arnm.Info
- Publication number
- MX2023004147A MX2023004147A MX2023004147A MX2023004147A MX2023004147A MX 2023004147 A MX2023004147 A MX 2023004147A MX 2023004147 A MX2023004147 A MX 2023004147A MX 2023004147 A MX2023004147 A MX 2023004147A MX 2023004147 A MX2023004147 A MX 2023004147A
- Authority
- MX
- Mexico
- Prior art keywords
- mrna
- lipid nanoparticles
- improved process
- provides
- present
- Prior art date
Links
- 108020004999 messenger RNA Proteins 0.000 title abstract 6
- 150000002632 lipids Chemical class 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 239000002105 nanoparticle Substances 0.000 title abstract 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- 238000005538 encapsulation Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Abstract
La presente invención proporciona un proceso mejorado para la formulación de nanopartículas lipídicas y la encapsulación de ARNm. En algunas modalidades, la presente invención proporciona un proceso para encapsular el ARN mensajero (ARNm) en nanopartículas lipídicas que comprende una etapa de mezclar una solución de ARNm que contiene una concentración baja de citrato y una solución lipídica a una temperatura ambiente. Por lo tanto, la presente invención proporciona un método eficaz, confiable, de ahorro de energía y rentable para encapsular el ARNm en nanopartículas lipídicas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063090513P | 2020-10-12 | 2020-10-12 | |
PCT/US2021/054527 WO2022081544A1 (en) | 2020-10-12 | 2021-10-12 | Improved process of preparing mrna-loaded lipid nanoparticles |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023004147A true MX2023004147A (es) | 2023-10-04 |
Family
ID=78516956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023004147A MX2023004147A (es) | 2020-10-12 | 2021-10-12 | Proceso mejorado de preparación de nanopartículas lipídicas cargadas de arnm. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220110884A1 (es) |
EP (1) | EP4225272A1 (es) |
JP (1) | JP2023545128A (es) |
KR (1) | KR20230087536A (es) |
CN (1) | CN116490166A (es) |
AU (1) | AU2021361986A1 (es) |
CA (1) | CA3198411A1 (es) |
IL (1) | IL301973A (es) |
MX (1) | MX2023004147A (es) |
WO (1) | WO2022081544A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7275111B2 (ja) | 2017-08-31 | 2023-05-17 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子の生成方法 |
WO2024015890A1 (en) * | 2022-07-13 | 2024-01-18 | Modernatx, Inc. | Norovirus mrna vaccines |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
FR2645866B1 (fr) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
US7799565B2 (en) | 2004-06-07 | 2010-09-21 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering RNA |
ES2937245T3 (es) | 2005-08-23 | 2023-03-27 | Univ Pennsylvania | ARN que contiene nucleósidos modificados y métodos de uso del mismo |
CN102245590B (zh) | 2008-10-09 | 2014-03-19 | 泰米拉制药公司 | 改善的氨基脂质和递送核酸的方法 |
EP2365962B1 (en) | 2008-11-07 | 2017-07-05 | Massachusetts Institute of Technology | Aminoalcohol lipidoids and uses thereof |
CA2764609C (en) | 2009-06-10 | 2018-10-02 | Alnylam Pharmaceuticals, Inc. | Improved cationic lipid of formula i |
EA022786B1 (ru) | 2009-07-31 | 2016-03-31 | Этрис Гмбх | Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков |
US20110244026A1 (en) | 2009-12-01 | 2011-10-06 | Braydon Charles Guild | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
EP4212514A1 (en) | 2011-06-08 | 2023-07-19 | Translate Bio, Inc. | Cleavable lipids |
PE20150041A1 (es) | 2011-10-27 | 2015-01-28 | Massachusetts Inst Technology | Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco |
EP2830595B1 (en) | 2012-03-29 | 2019-10-16 | Translate Bio, Inc. | Ionizable cationic lipids |
BR112015022505A2 (pt) | 2013-03-14 | 2017-10-24 | Shire Human Genetic Therapies | avaliação quantitativa para eficiência do cap de rna mensageiro |
EA201591229A1 (ru) | 2013-03-14 | 2016-01-29 | Шир Хьюман Дженетик Терапис, Инк. | Способы очистки матричной рнк |
US10059655B2 (en) | 2013-12-19 | 2018-08-28 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
KR102470198B1 (ko) | 2014-04-25 | 2022-11-22 | 샤이어 휴먼 지네틱 테라피즈 인크. | 메신저 rna 의 정제 방법 |
MA48050A (fr) | 2014-05-30 | 2020-02-12 | Translate Bio Inc | Lipides biodégradables pour l'administration d'acides nucléiques |
HUE060907T2 (hu) | 2014-06-25 | 2023-04-28 | Acuitas Therapeutics Inc | Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére |
CA2953265C (en) * | 2014-07-02 | 2023-09-26 | Shire Human Genetic Therapies, Inc. | Encapsulation of messenger rna |
US9840479B2 (en) | 2014-07-02 | 2017-12-12 | Massachusetts Institute Of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
WO2016118724A1 (en) | 2015-01-21 | 2016-07-28 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
WO2016118725A1 (en) | 2015-01-23 | 2016-07-28 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
EP3310764B1 (en) | 2015-06-19 | 2023-04-19 | Massachusetts Institute of Technology | Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell |
DK3313829T3 (da) | 2015-06-29 | 2024-06-17 | Acuitas Therapeutics Inc | Lipider og lipide nanopartikelformuleringer til levering af nukleinsyrer |
RS63030B1 (sr) | 2015-09-17 | 2022-04-29 | Modernatx Inc | Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava |
HUE061564T2 (hu) | 2015-10-28 | 2023-07-28 | Acuitas Therapeutics Inc | Új lipidek és lipid nanorészecske készítmények nukleinsavak bevitelére |
US20190022247A1 (en) | 2015-12-30 | 2019-01-24 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
JP7245651B2 (ja) | 2016-03-30 | 2023-03-24 | インテリア セラピューティクス,インコーポレイテッド | Crispr/cas構成成分のための脂質ナノ粒子製剤 |
CA3043033A1 (en) | 2016-11-10 | 2018-05-17 | Translate Bio, Inc. | Improved ice-based lipid nanoparticle formulation for delivery of mrna |
CA3041345A1 (en) | 2016-11-10 | 2018-05-17 | Shrirang KARVE | Improved process of preparing mrna-loaded lipid nanoparticles |
AU2018224843A1 (en) | 2017-02-27 | 2019-09-19 | Translate Bio, Inc. | Methods for purification of messenger RNA |
EP3585892B8 (en) | 2017-02-27 | 2022-07-13 | Translate Bio, Inc. | Methods for purification of messenger rna |
EP4105326A1 (en) | 2017-02-27 | 2022-12-21 | Translate Bio, Inc. | Large scale synthesis of messenger rna |
WO2018213476A1 (en) | 2017-05-16 | 2018-11-22 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
AU2019333042A1 (en) * | 2018-08-29 | 2021-03-04 | Translate Bio, Inc. | Improved process of preparing mRNA-loaded lipid nanoparticles |
CA3140423A1 (en) * | 2019-05-14 | 2020-11-19 | Translate Bio, Inc. | Improved process of preparing mrna-loaded lipid nanoparticles |
-
2021
- 2021-10-12 KR KR1020237015826A patent/KR20230087536A/ko unknown
- 2021-10-12 WO PCT/US2021/054527 patent/WO2022081544A1/en active Application Filing
- 2021-10-12 IL IL301973A patent/IL301973A/en unknown
- 2021-10-12 CA CA3198411A patent/CA3198411A1/en active Pending
- 2021-10-12 AU AU2021361986A patent/AU2021361986A1/en active Pending
- 2021-10-12 US US17/450,629 patent/US20220110884A1/en active Pending
- 2021-10-12 MX MX2023004147A patent/MX2023004147A/es unknown
- 2021-10-12 CN CN202180078195.XA patent/CN116490166A/zh active Pending
- 2021-10-12 JP JP2023521832A patent/JP2023545128A/ja active Pending
- 2021-10-12 EP EP21802521.1A patent/EP4225272A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220110884A1 (en) | 2022-04-14 |
EP4225272A1 (en) | 2023-08-16 |
KR20230087536A (ko) | 2023-06-16 |
CN116490166A (zh) | 2023-07-25 |
IL301973A (en) | 2023-06-01 |
CA3198411A1 (en) | 2022-04-21 |
AU2021361986A1 (en) | 2023-06-15 |
WO2022081544A1 (en) | 2022-04-21 |
JP2023545128A (ja) | 2023-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023004147A (es) | Proceso mejorado de preparación de nanopartículas lipídicas cargadas de arnm. | |
MX2021013959A (es) | Proceso mejorado de preparación de nanopartículas lipídicas cargadas de arnm. | |
Ocsoy et al. | Biomolecules incorporated metallic nanoparticles synthesis and their biomedical applications | |
DE602005021756D1 (de) | Partikel mit kern aus calciumphosphat-nanopartikeln, biomolekül und gallensäure, herstellungsverfahren und therapeutische verwendung | |
BR112016030852A2 (pt) | encapsulação de rna mensageiro | |
NZ535687A (en) | Encapsulated agglomeration of microcapsules and method for the preparation thereof | |
EP2261957A3 (en) | Substrate treating method and method of manufacturing semiconductor device using the same | |
IL174184A0 (en) | Stable beadlets of lipophilic nutrients | |
EP1104309B8 (en) | Co-lyophilized complex comprising a nucleic acid vector and a formulating agent | |
KR101800859B1 (ko) | 미백개선 유효물질이 봉입된 나노입자, 이의 제조방법 및 이를 유효성분으로 함유하는 미백개선용 화장료 조성물 | |
MY162202A (en) | Methods of treating a semiconductor layer | |
AU2001257305A1 (en) | Hematology blood control and method for preparation of same | |
CN108281359A (zh) | 一种键合丝的有机防氧化方法 | |
Meng et al. | Temperature effect of plasmonic circular dichroism in dynamic oligomers of AuNR@ Ag nanorods driven by cysteine: the role of surface atom migration | |
CN101559972A (zh) | 硫化银纳米颗粒的制备方法 | |
CN109490522A (zh) | 一种纳米胶体金及其制备方法与应用 | |
Yang et al. | Hepatotoxicity induced by ZnO quantum dots in mice | |
Britto et al. | Analysis of thermal and aqueous suspension stabilities of chitosan based nanoencapsulated vitamins | |
CN110028072A (zh) | 一种锰掺杂介孔二氧化硅纳米粒的制备方法 | |
CN114469862A (zh) | 胆固醇调控包封聚多巴胺的方法 | |
de Barros et al. | Assembly of Nano‐Biocatalyst for the Tandem Hydrolysis and Reduction of p‐Nitrophenol Esters | |
CN106880594A (zh) | 囊泡的简便制备方法及其在药物缓/控释中的应用 | |
Jung et al. | Observation of blip response in a single Pt nanoparticle collision on a Cu ultramicroelectrode | |
CN107179344A (zh) | 过氧化氢传感器、其制备方法及应用 | |
TW200727364A (en) | Method for preparing gate oxide layer |